secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001104659-22-125852
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until June 2023
--------------------------------------------------------------------------------

- Nasdaq notified TransCode on Dec 9, 2022 that common stock failed minimum $1.00 bid price for 30 consecutive days through Dec 8.
- Company has until June 7, 2023 to regain compliance; bid price must close at $1.00+ for 10 consecutive business days.
- If not cured, Company may qualify for additional 180-day period or face delisting; possible reverse stock split considered.
- No immediate delisting; Company intends to monitor and explore options to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465922125852/0001104659-22-125852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465922125852/tm2232381d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-125852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer